Alumis reaches new efficacy levels in oral TYK2 inhibitor field

Alumis is joining the oral TYK2 inhibitor race in psoriasis, and it’s making a strong entrance, with Phase II data showing a response level that hasn’t been achieved by other therapies in the class.

Less than a week after announcing an upsized $259 million series C round, Alumis Inc. reported that 90% of patients at the highest dose of ESK-001, 40 mg twice daily, had received at least 75% skin clearance after 16 weeks in the Phase II STRIDE open-label extension study...